AGA technical review on irritable bowel syndrome.
- D. Drossman, M. Camilleri, E. Mayer, W. Whitehead
- Medicine, PsychologyGastroenterology
- 1 December 2002
Psychosocial factors, although not part of IBS per se, have an important role in modulating the illness experience and its clinical outcome.
A System Model of Oral Glucose Absorption: Validation on Gold Standard Data
- C. Man, M. Camilleri, C. Cobelli
- BiologyIEEE Transactions on Biomedical Engineering
- 20 November 2006
The recent availability of Ra data is utilized, estimated with a model-independent multiple tracer technique, to formulate a system model of intestinal glucose absorption, which has important potential both in simulation contexts and in clinical studies to quantitatively characterize possible impairment of glucose absorption in particular populations such as elderly and diabetic individuals.
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating
- H. J. Kim, M. V. Vazquez Roque, A. Zinsmeister
- MedicineNeurogastroenterology and Motility
- 1 October 2005
Abstract Aim: To evaluate the effects of a combination probiotic on symptoms and colonic transit in patients with irritable bowel syndrome (IBS) and significant bloating.
A placebo-controlled trial of prucalopride for severe chronic constipation.
- M. Camilleri, R. Kerstens, A. Rykx, L. Vandeplassche
- Medicine, PsychologyNew England Journal of Medicine
- 29 May 2008
Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation.
Clinical Guideline: Management of Gastroparesis
- M. Camilleri, H. Parkman, Mehnaz A. Shafi, T. Abell, L. Gerson
- MedicineAmerican Journal of Gastroenterology
- 2013
Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES), do not adequately address clinical need and attention should be given to the development of new effective therapies for symptomatic control.
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndrome
- H. Kim, M. Camilleri, A. Zinsmeister
- MedicineAlimentary Pharmacology and Therapeutics
- 1 April 2003
Aim : To investigate the effects of a probiotic formulation, VSL#3, on gastrointestinal transit and symptoms of patients with Rome II irritable bowel syndrome with predominant diarrhoea.
Irritable bowel syndrome: a technical review for practice guideline development.
- D. Drossman, W. Whitehead, M. Camilleri
- MedicineGastroenterology
- 1 June 1997
Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation
- S. Kane, W. Sandborn, S. Hanauer
- MedicineAmerican Journal of Gastroenterology
- 1 June 2003
Fecal lactoferrin is sensitive and specific for detecting inflammation in chronic IBD and may prove useful in screening for inflammation in patients presenting with abdominal pain and diarrhea.
Mechanisms of hypersensitivity in IBS and functional disorders
- F. Azpiroz, M. Bouin, R. Spiller
- MedicineNeurogastroenterology and Motility
- 1 January 2007
This article addresses the proposed mechanisms leading to hypersensitivity: from genetic to inflammatory disorders, from central to peripheral alterations of function, and the peripheral and central mechanisms involved and the role of inflammation on hypersensitivity.
Intestinal barrier function in health and gastrointestinal disease
- M. Camilleri, K. Madsen, R. Spiller, B. G. Van Meerveld, G. Verne
- MedicineNeurogastroenterology and Motility
- 1 June 2012
This review takes a unique translational approach to discuss the physiological and pathophysiological mechanisms involved in the regulation of intestinal barrier function in IBS, and summarizes the components of the intestinal barrier including the tight junction complex within the epithelium.
...
...